Classification criteria and treatment modalities in primary Sjögren’s syndrome
| Autor: | Arnaud Theulin, Jean Sibilia, Emmanuel Chatelus, Alia Fazaa, Tristan Bourcier, Jacques-Eric Gottenberg, Christelle Sordet |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pediatrics
medicine.medical_specialty Consensus business.industry Abatacept Immunology Disease Belimumab Rheumatology Clinical trial chemistry.chemical_compound Sjogren's Syndrome Tocilizumab chemistry Treatment modality Internal medicine medicine Physical therapy Humans Immunology and Allergy Rituximab business medicine.drug |
| Zdroj: | Expert Review of Clinical Immunology. 10:543-551 |
| ISSN: | 1744-8409 1744-666X |
| Popis: | Primary Sjögren's syndrome is a systemic autoimmune disease, characterized by a lymphocytic exocrinopathy. Oral and ocular dryness, asthenia and pain represent hallmarks of the disease. Systemic manifestations concern a third of patients, including lymphoma in 5% of the patients. The American European Consensus Group classification criteria have been used in current practice and clinical trials since 2002. New classification criteria were recently proposed by the American Congress of Rheumatology. A group of international experts are currently working to reach a new consensus between the American European Consensus Group classification criteria and the American Congress of Rheumatology proposal for disease classification. In addition, international consensus disease activity scores were recently established. Regarding treatment modalities, symptomatic treatments remain the cornerstone of therapy in pSS, but new biologic treatments are currently evaluated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|